“To do that we had to bind the molecules by one extremity to a solid support—to anchor them,” he recounts. “We succeeded, but it was difficult to bind a single bead. One day, I saw themeniscus, the interface between the air and the water, stretch the DNA—a phenomena we call DNA combing.”
Put simply, the combing process essentially arranges DNA strands in a uniform way—Bensimon describes them as “bar codes.” By using a fluorescent substance to “tag” the strands, the researchers were able to isolate specific genes and more easily hunt for aberrations in the DNA that would be indicative of genetic mutuations.
“I realized pretty quickly that the discovery would help the identification of genetic diseases,” explains Bensimon. Deciding to make the jump from researcher to entrepreneur, he negotiated with Pasteur Institute to gain an exclusive license on his patent portfolio and launched Genomic Vision in 1995. Since the Human Genome Project—the blueprinting of the human genome—would not be completed until 2003, Bensimon faced an uphill battle in getting the world to understand his invention’s potential.
“I would present DNA combing process to the scientific community and people would say, ‘It’s cute,’” he recounts. “I would say, ‘No, it’s not cute. It’s a revolution in terms of what you can do with it.’ I began to understand that while inventors may understand what they can do with their invention, the environment doesn’t always see it. It’s very frustrating to make an avant-garde discovery—one that’s ahead of science in the current environment.”
A turning point came when a French professor who had read about DNA combing contacted Bensimon to explore the idea of using his discovery to aid in the diagnosis of facioscapulohumeral
muscular dystrophy (FSHD). In time, that conversation led to the 2013 launch of Genomic Vision’s first commercialized test—which, in turn, led to a pivotal alliance with Quest Diagnostics to
provide the FSHD test in the U.S., India and Mexico and to partner with Genomic Vision on its research. That accomplishment, however, is just the beginning of Genomic Vision’s potential, says Bensimon.
“FSHD is a rare disease, so it’s not the test that will bring major income,” he explains. “Our blockbusters will be tests for breast cancer, cervical cancer and colon cancer.” Genomic Vision’s strategic plan calls for revenues from these tests to be $500 million, $100 million and $300 million, respectively, in the U.S. alone.
While transitioning from the research world into entrepreneurship put Bensimon on a demanding learning curve, it’s one he has navigated admirably, managing to attract investors and then raise an additional 23 million euros by taking the company public in April of 2014. “I read a lot of books,” he recalls. “I also took an MBA-like course designed for entrepreneurs in France. So I had some tools, but what you really need is perseverance and some of a kind of internal drive where you just won’t give up on what you believe in.”